A research team has designed a molecule with potential to interfere in a new way with altered proteins that cause abnormal growth in 35% of pancreatic cancers.
While doing somewhat-routine reporting on this year’s Senate Appropriations Committee bills, Paul Goldberg, editor and publisher of The Cancer Letter, quickly realized that he was seeing a full bipartisan rejection of President Donald J. Trump’s plan to defund and therefore dismantle biomedical research in the United States.
